Xilio Therapeutics (XLO) Cash & Equivalents (2020 - 2026)

Xilio Therapeutics has reported Cash & Equivalents for 7 years, with the latest figure at $150.3 million in Q1 2026.

• Quarterly Cash & Equivalents rose 68.74% year-over-year to $150.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $150.3 million (up 68.74% YoY) and the FY2025 annual result came in at $137.5 million, up 148.74% from the prior year.
• Cash & Equivalents grew to $150.3 million in Q1 2026 per XLO's latest filing, from $137.5 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $177.0 million in Q1 2022 and troughed at $34.0 million in Q1 2024.
• A 5-year average of $99.8 million and a median of $93.3 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents slumped 63.57% in 2024, then soared 162.13% in 2025.
• Over 5 years, Cash & Equivalents stood at $120.4 million in 2022, then sank by 62.87% to $44.7 million in 2023, then rose by 23.68% to $55.3 million in 2024, then surged by 148.74% to $137.5 million in 2025, then grew by 9.28% to $150.3 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $150.3 million, $137.5 million, and $103.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.